93 results
PRE 14A
ONCR
Oncorus, Inc.
12 Jun 23
Preliminary proxy
6:33am
in this proxy statement regarding tax consequences are general in nature.
We have not requested a ruling from the IRS with respect to the anticipated … .
The description of the Dissolution contained in this introductory section is general in nature and is subject to various other factors and requirements
8-K
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
Nature Communications highlighting the potential of its self-amplifying RNA platform as a novel approach to treating cancer by enabling repeat intravenous
8-K
EX-99.1
199n2hd44cm 5q8s
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
8-K
EX-99.1
c4f8aeeq ez6
2 Nov 22
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
7:11am
8-K
EX-4.1
ql7tb4r9y enzme
5 Apr 22
Entry into a Material Definitive Agreement
7:10am
8-K
EX-10.1
lat oywwayw
5 Apr 22
Entry into a Material Definitive Agreement
7:10am